Literature DB >> 12426224

Metabolism of apoA-I as lipid-free protein or as component of discoidal and spherical reconstituted HDLs: studies in wild-type and hepatic lipase transgenic rabbits.

Patrick Kee1, Kerry-Anne Rye, John L Taylor, P Hugh R Barrett, Philip J Barter.   

Abstract

OBJECTIVE: Apolipoprotein (apo)A-I exists in 3 forms in plasma: as lipid-free apoA-I, as a component of pre-beta-migrating discoidal high density lipoproteins (HDLs), and as a component of alpha-migrating spherical HDLs. This study investigates (1) the in vivo metabolism of apoA-I in each of these forms and (2) the effects of hepatic lipase (HL) on apoA-I metabolism. METHODS AND
RESULTS: Wild-type and HL transgenic rabbits were studied. When lipid-free (125)I-apoA-I and 125I-apoA-I in pre-beta-migrating discoidal reconstituted HDLs (rHDLs) were injected into wild-type rabbits, the label rapidly appeared in alpha-migrating particles and decayed with the same fractional catabolic rate (FCR) as when they were injected as a component of spherical rHDLs. Spherical rHDLs did not change in size when they were injected into wild-type rabbits but were reduced in size in HL transgenic rabbits. The FCR of apoA-I in HL transgenic rabbits was double that in wild-type rabbits.
CONCLUSIONS: In vivo, (1) lipid-free apoA-I rapidly incorporates into preexisting alpha-migrating particles, (2) pre-beta-migrating discoidal HDLs are rapidly converted into alpha-migrating HDLs, (3) the FCR of apoA-I is independent of the form in which it is introduced into plasma, and (4) HL reduces the size of alpha-migrating HDLs and increases the rate of catabolism of apoA-I.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12426224     DOI: 10.1161/01.atv.0000038485.94020.7f

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  18 in total

Review 1.  New insights into the role of HDL as an anti-inflammatory agent in the prevention of cardiovascular disease.

Authors:  Philip J Barter; Rajesh Puranik; Kerry-Anne Rye
Journal:  Curr Cardiol Rep       Date:  2007-11       Impact factor: 2.931

2.  Methionine oxidized apolipoprotein A-I at the crossroads of HDL biogenesis and amyloid formation.

Authors:  Andrzej Witkowski; Gary K L Chan; Jennifer C Boatz; Nancy J Li; Ayuka P Inoue; Jaclyn C Wong; Patrick C A van der Wel; Giorgio Cavigiolio
Journal:  FASEB J       Date:  2018-01-17       Impact factor: 5.191

Review 3.  HDL-targeted therapies: progress, failures and future.

Authors:  Bronwyn A Kingwell; M John Chapman; Anatol Kontush; Norman E Miller
Journal:  Nat Rev Drug Discov       Date:  2014-05-23       Impact factor: 84.694

Review 4.  Speciated High-Density Lipoprotein Biogenesis and Functionality.

Authors:  C Rosales; W S Davidson; B K Gillard; A M Gotto; H J Pownall
Journal:  Curr Atheroscler Rep       Date:  2016-05       Impact factor: 5.113

5.  Influence of route of administration and lipidation of apolipoprotein A-I peptide on pharmacokinetics and cholesterol mobilization.

Authors:  Jie Tang; Dan Li; Lindsey Drake; Wenmin Yuan; Sara Deschaine; Emily E Morin; Rose Ackermann; Karl Olsen; David E Smith; Anna Schwendeman
Journal:  J Lipid Res       Date:  2016-11-23       Impact factor: 5.922

6.  Oxidation of methionine residues in human apolipoprotein A-I generates a potent pro-inflammatory molecule.

Authors:  Andrzej Witkowski; Sonia Carta; Rui Lu; Shinji Yokoyama; Anna Rubartelli; Giorgio Cavigiolio
Journal:  J Biol Chem       Date:  2019-01-11       Impact factor: 5.157

7.  Acylation of lysine residues in human plasma high density lipoprotein increases stability and plasma clearance in vivo.

Authors:  Yaliu Yang; Corina Rosales; Baiba K Gillard; Antonio M Gotto; Henry J Pownall
Journal:  Biochim Biophys Acta       Date:  2016-09-02

Review 8.  Rethinking reverse cholesterol transport and dysfunctional high-density lipoproteins.

Authors:  Baiba K Gillard; Corina Rosales; Bingqing Xu; Antonio M Gotto; Henry J Pownall
Journal:  J Clin Lipidol       Date:  2018-04-12       Impact factor: 4.766

Review 9.  Why targeting HDL should work as a therapeutic tool, but has not.

Authors:  Mary G Sorci-Thomas; Michael J Thomas
Journal:  J Cardiovasc Pharmacol       Date:  2013-09       Impact factor: 3.105

10.  Initial interaction of apoA-I with ABCA1 impacts in vivo metabolic fate of nascent HDL.

Authors:  Anny Mulya; Ji-Young Lee; Abraham K Gebre; Elena Y Boudyguina; Soon-Kyu Chung; Thomas L Smith; Perry L Colvin; Xian-Cheng Jiang; John S Parks
Journal:  J Lipid Res       Date:  2008-06-25       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.